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Abstract
Background: In B-cell precursor acute lymphoblastic leukemia (BCP-ALL) PAX5, a transcription factor pivotal for
B-cell commitment and maintenance, is frequently affected by genetic alterations. In 2-3 % of the cases PAX5
rearrangements result in the expression of oncogenic fusion genes. The encoded chimeric proteins consist of
the N-terminal PAX5 DNA-binding paired domain, which is fused to the C-terminal domains of a remarkable
heterogeneous group of partner proteins.
Results: Employing fluorescence in situ hybridization and molecular methods PAX5-KIAA1549L was identified as
novel fusion gene in a case of pediatric BCP-ALL.
Conclusion: Our report underlines the high diversity of PAX5 fusion partners in BCP-ALL and we describe the
second involvement of KIAA1549L in a genetic rearrangement in acute leukemia.
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Background
Acute lymphoblastic leukemia (ALL) is the most common
childhood malignancy and one of the leading causes of
cancer-related death in children and young adults. ALL is
characterized by a plethora of somatic mutations, which
are involved in the pathogenesis and progression of the
disease [1]. In this regard, in childhood B-cell precursor
ALL (BCP-ALL) PAX5, a transcription factor crucial for
B-cell commitment and maintenance [2], is frequently
affected by genetic alterations comprising deletions,
point mutations, amplifications, and chromosomal re-
arrangements [3–7]. The latter occur in 2-3 % of the
cases and result in the expression of chimeric proteins
consisting of the PAX5 DNA-binding paired domain
(PD) at the N-terminus, fused to the C-terminal domains
of a highly diverse group of partner proteins [3–5, 8]. A
multitude of functionally different PAX5 partners, including
transcription factors, chromatin regulators, protein kinases,
and structural proteins, have been identified and to date
more than 20 in-frame PAX5 fusions have been described
[3–5, 8–15]. The unifying feature of all PAX5 chimeras,
which are generally suggested to act as aberrant transcrip-
tion factors antagonizing wild-type PAX5 function, is the
retention of the DNA-binding domain [2, 3, 9, 16–18].
However, the partner protein appears to modulate the
function of the different PAX5 fusion proteins, suggesting
differences in the development of the respective leukemia
[19, 20]. In this work we describe a novel PAX5 rearrange-
ment in a case of pediatric BCP-ALL in which PAX5 is
fused to KIAA1549L.
Case presentation
A 2.2-year old girl was diagnosed with BCP-ALL. The
bone marrow and the peripheral blood showed an infil-
tration with 94 % and 89 % blast cells of L1 morphology,
respectively. Immunophenotyping demonstrated CD19+,
CD10+, cyCD22+, HLA-DR+, TdT+, cyIgM+, mIgM-,
MPO-, CD34-, CD14-, CD13-, CD33-, cyCD3-, and
CD7- blast cells with coexpression of the myeloid
marker CDw65 on 20 % of them. Cytogenetic and molecu-
lar analyses showed a normal 46,XX[20] karyotype and* Correspondence: sabine.strehl@ccri.at
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negativity for the ETV6-RUNX1, KMT2A-AFF1 (alias
MLL-AF4), BCR-ABL1, and TCF3-PBX1 fusion genes.
The patient was enrolled in the ALL-BFM 95 study
(ClinicalTrials.gov Identifier: NCT00411541) and treated
in the intermediate risk arm of the protocol [21, 22].
The patient was randomized into the methotrexate and
cytarabine (MCA) protocol, which included an intensifica-
tion of the extracompartement phase with an intermediate
dose cytarabine in addition to high-dose methotrexate.
For maintenance therapy the patient was randomized into
the treatment arm, which received an intensified therapy
with additional pulses of dexamethasone and vincristine.
The patient is in long-term remission 8.6 years after initial
diagnosis.
Material and methods
Cytogenetic and fluorescence in situ hybridization (FISH)
analysis
Cytogenetic and FISH analyses were performed accord-
ing to standard techniques. FISH was conducted using
PAX5 exon-specific cosmid probes cos-hPAX5-1 (exons
2–5) and cos-hPAX5-3 (exons 9-10) as previously de-
scribed [4].
Rapid amplification of cDNA ends (RACE) and reverse
transcription-polymerase chain reaction (RT-PCR)
RNA isolation was performed with the Qiagen RNeasy
Mini-Kit (Qiagen, Germany) following the manufac-
turer’s instructions. RACE ready cDNA was generated
using 220 ng total RNA input and the SMARTer™ RACE
cDNA Amplification Kit (Clontech/Takara, France). 3′-
RACE-PCR and 3′-nested RACE-PCR were performed
with the Advantage 2 PCR Kit (Clontech/Takara, France)
and standard PCR reagents (Sigma, Austria), respectively.
RT-PCR for the detection of PAX5-KIAA1549L tran-
scripts was performed according to standard procedures
using primers located in exon 5 of PAX5 (PAX5ex5_F1
5′-TACTCCATCAGCGGCATCC-3′) and exon 20 of
KIAA1549L (KIAA1549Lex20_R2: 5′-AACACGTAGGC
ATGGGAAAC-3′). Amplification products were directly
sequenced (Microsynth AG, Austria) and sequence ana-
lysis was conducted using the CLC Main Workbench 6.0
(CLC bio, Denmark).
Reference sequences, exon nomenclature, and protein
analysis
The exon nomenclature used corresponds to that of
the NCBI database (accessed December 2014) and the
reference sequences NM_016734.2 for PAX5 and
NM_012194 for KIAA1549L were used. Protein motif
search was performed with Psort II Prediction [23] and
NCBI_Protein [24]. The conservation of KIAA1549L
across species was derived from NCBI_HomoloGene [25].
Detection of copy number alterations (CNAs)
Genome-wide CNAs were determined using the Cyto-
Scan HD array platform (Affymetrix, USA). This array
platform contains 2.67 million probes, including 1.9 mil-
lion copy number probes and 0.75 million SNP probes.
Array analysis and interpretation was conducted with
the Chromosome Analysis Suite (ChAS 2.0.0) software
(Affymetrix, USA). Genome segment filters were set to a
marker count of 50 and a size of 50 kb for gains and
losses. The ChAS Browser Annotations version NetAffx
built 32.3 (UCSC genome assembly hg19) was used for
analysis.
Results and discussion
FISH analysis of the diagnostic bone marrow using
PAX5-specific probes showed a deletion of the PAX5 3’-
end in 72 % of the interphase cells, which is highly
suggestive of the presence of a PAX5 fusion gene
(Fig. 1a). 3’-RACE-PCR and subsequent verification by
RT-PCR identified KIAA1549L (alias C11orf41), located
at 11p13, as novel PAX5 fusion partner (Fig. 1b).
Sequence analysis revealed an in-frame PAX5-KIAA1549L
fusion transcript in which exon 6 of PAX5 is fused to
exon 16 of KIAA1549L (Fig. 1c). The predicted fusion
protein retains the DNA-binding paired domain (PD),
the octapeptide motif, the nuclear localization signal,
and the homeodomain of PAX5, which are fused to
the C-terminus of KIAA1549L (Fig. 1d).
KIAA1549L is a 1849 amino acids long protein with
highly conserved regions whose functions have not been
determined yet. As predicted by protein motif search,
KIAA1549L harbors only a potential transmembrane
domain encoded by exon 10, which, however, is not
retained in the PAX5-KIAA1549L chimera. KIAA1549L
is preferentially expressed in the human cerebral cortex
and immunohistochemistry data suggest that KIAA1549L
is localized in the nucleus as well as in cytoplasmatic vesi-
cles [26, 27].
The opposite orientation of the partner genes –
PAX5 centromere-telomere and KIAA1549L telomere-
centromere – excludes the formation of the PAX5-
KIAA1549L fusion by a simple reciprocal translocation
and their location and orientation suggested the pres-
ence of a dic(9;11) chromosome. Since the lack of
metaphases precluded a detailed FISH analysis of the
chromosomes involved in the rearrangement, we ana-
lyzed the genomic DNA using the CytoScan HD array,
which – apart from the genome-wide detection of copy
number alterations (CNAs) – permits to uncover un-
balanced translocations. However, in contrast to PAX5-
ETV6 and PAX5-C20orf112, which are generated by
the formation of dic(9;12) and dic(9;20) chromosomes,
respectively [12, 28], in case of PAX5-KIAA1549L the
CNAs did not corroborate the presence of a dic(9;11).
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Instead of losses of almost the entire p-arms of chro-
mosomes 9 and 11, which would reflect the presence
of a dic(9;11), we observed only minor deletions on
the involved chromosomes (Fig. 1e). Consequently,
similarly to other PAX5 fusions [4, 8], also the PAX5-
KIAA1549L fusion is most likely generated by a com-
plex rearrangement.
A more detailed analysis of the CNAs of chromosomes
9 and 11 revealed a 324 kb heterozygous deletion on
chromosome 9, which – amongst other genes – affected
PAX5 exons 7–10, and a 578 kb heterozygous deletion
on chromosome 11, including KIAA1549L exons 1–15
(Fig. 1f ). In line with the molecular analysis of the
PAX5-KIAA1549L fusion gene (Fig. 1c), PAX5 exons 1–6
and KIAA1549L exons 16–20, which are present in the
fusion gene, were retained (Fig. 1f ). These data indicate
that only PAX5-KIAA1549L but no reciprocal transcripts
are expressed, which supports the previous finding that
in most PAX5-rearranged cases only PAX5 fusion tran-
scripts but no corresponding reciprocal ones are detect-
able [4, 8, 29].
With regard to other CNAs and in line with previous
findings in PAX5-rearranged leukemia [8], we generally
detected only a few minor gains and losses (Additional
file 1). Chromosome 9 showed an additional heterozy-
gous loss of a 4760 kb region at 9p21, within which we
observed a smaller homozygous deletion affecting
CDKN2A/B (Fig. 1e, Fig. 2a, Additional file 1). CDKN2A/
B is commonly deleted in ALL [30] and its hetero- or
homozygous loss is also frequently observed in dic(9;20)
leukemia [31–33], which in some cases expresses the
PAX5-C20orf112 fusion gene [12, 32, 34, 35]. Furthermore,
formation of the dic(9;12) resulting in the expression of
the PAX5-ETV6 fusion is invariably associated with a het-
erozygous deletion of CDKN2A/B as well [28, 35]. There-
fore, loss of CDKN2A/B may represent a secondary
Fig. 1 Cytogenetic and molecular analysis of PAX5-KIAA1549L. a Interphase FISH using PAX5 exon-specific cosmid probes cos-hPAX5-1 (exons 2–5,
red signals) and cos-hPAX5-3 (exons 9–10, green signals) showing loss of a PAX5 3’-end. b RT-PCR using primers specific for PAX5 exon 5 and KIAA1549L
exon 20 resulting in amplification of PAX5-KIAA1549L fusion transcripts. Sequencing of the second smaller band, indicated by an asterisk (*), revealed a
splice variant of PAX5-KIAA1549L, lacking exon 16 of KIAA1549L. M, molecular weight marker DNA ladder-mix (Peqlab); lane 1, patient; lane 2, normal
control; lane 3, water control. c Sequence analysis of the predominant RT-PCR product showing the presence of an in-frame fusion between PAX5 exon
6 and KIAA1549L exon 16. d Schematic representation of the PAX5 wild-type and the PAX5-KIAA1549L proteins. PD, paired domain; 8, octapeptide; HD,
partial homeodomain; TA, transactivation domain; ID, inhibitory domain; arrows indicate the nuclear localization signal of PAX5; aa, amino acids. e
Chromosomes 9 and 11 with areas of genetic loss (red) detected by the CytoScan HD array and selected genes included in these areas. f Detailed view of
PAX5 on chromosome 9 (left panel) and KIAA1549L on chromosome 11 (right panel). The blue dashed lines indicate the breakpoints and the transitions
from areas with normal and deleted (red bars) copy number states. The retained exons 1–6 of PAX5 and exons 16–20 of KIAA1549L correspond to the
fusion gene detected by RT-PCR
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genetic lesion that cooperates at least with a subset of
PAX5 fusions in the development of BCP-ALL.
Remarkably, chromosome X displayed a heterozygous
loss of almost an entire p-arm and a gain of one copy of
the entire q-arm, indicating the presence of an isodicentric
idic(X)(p11) chromosome (Fig. 2c, Additional file 1).
While idic(X)(q13) chromosomes are recurrently found in
myeloid malignancies [36], an idic(X)(p11) is an extremely
Fig. 2 Detailed view of gains and losses of chromosomes 9, 11, and X. a Chromosome 9. The heterozygous 4760 kb deletion includes a homozygous
deletion of CDKN2A/B indicated by the decrease of the smooth signal to zero. The smaller heterozygous loss affects, amongst other genes, the 3’-end
of PAX5. b Chromosome 11. The heterozygous deletion at 11p13 includes the 5’-end of KIAA1549L. c Chromosome X. The changes of the
log2 ratios along the chromosome indicate a trisomy of the entire q-arm and a small part of the p-arm as well as loss of most of the
p-arm, indicating the presence of an idic(X)(p11)
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rare chromosome abnormality, which according to the
Mitelman database [37] has only been described in a
single case of Burkitt lymphoma [38].
Since PAX5 fusions in ALL are rather rare [4, 5], their
prognostic relevance per se and also the impact of
secondary alterations including loss of CDKN2A/B remain
to be determined. However, in this context it appears that
PAX5 deletions and mutations are not associated with
clinical outcome [39] and that the prognostic value of
CDKNA/B deletions is cytogenetic subtype and copy
number alteration profile dependent [30, 40].
Involvement of KIAA1549L in another chromosome
translocation has been previously reported in an adult
case of acute myeloid leukemia with a t(11;21)(p14;q22)
resulting in a RUNX1-KIAA1549L fusion [41]. In con-
trast to the RUNX1-KIAA1549L fusion, in which alterna-
tively spliced RUNX1 sequences are fused to exon 13 of
KIAA1549L, PAX5 exon 6 is fused to exon 16, indicating
different genomic breakpoints in introns 12 and 15 of
KIAA1549L, respectively. Furthermore, KIAA1549, a
homolog of KIAA1549L, is involved in the recurrent
KIAA1549-BRAF fusion gene found in pediatric and
adult pilocytic astrocytoma [42].
In summary, we here describe a novel PAX5 fusion
partner and the second involvement of KIAA1549L in a
leukemic fusion gene, indicating that it may play a so
far underestimated role in the development of acute
leukemia.
Conclusion
In this study we identified KIAA1549L as novel PAX5
fusion partner, which, on the one hand, increases the
number of PAX5 fusion partners found in BCP-ALL, and,
on the other hand, shows that KIAA1549L is involved
in at least two different fusion genes, emphasizing its
potential role in the pathogenesis of acute leukemia.
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